ArticleScience (New York, N.Y.)2024
Systematic in vitro evolution in
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- High-throughput screening and meta-analysis for lead compounds in antimalarial drug discovery.Malaria journal · 2025Pooled it
- MalDeepSeq panel: A targeted ultra-deep sequencing approach to trace drug resistance markers in Plasmodium falciparum.Cell reports methods · 2026Article
- New thinking for the next generation of antimalarials.EMBO molecular medicine · 2026Review
- Plasmodium falciparum HSP90 inhibitors show divergent resistance despite a shared ATP-binding site.Cell reports · 2026Article
- Using Unbiased Chemical Proteomics Approaches to Explore the Target Landscape of the Resistance Refractory 7-Azaindole MMV022224 inACS infectious diseases · 2026Article
- Revisiting 2-Substituted-4(1Journal of medicinal chemistry · 2026Article
- Gain-of-function PfAAT1 mutations compensate for impaired PfCRT function inResearch square · 2026Article
- Single-cell analysis ofbioRxiv : the preprint server for biology · 2026Article
- Article
- Replication stress increases de novo CNVs across the malaria parasite genome.Nucleic acids research · 2026Article
- Emergence of chloroquine-sensitiveEmerging microbes & infections · 2025Article
- Heterogeneous constraint and adaptation across the malaria parasite life cycle.Proceedings. Biological sciences · 2025Article
- Identification of α-Azacyclic Acetamide-Based Inhibitors ofACS infectious diseases · 2025Article
- Replication stress increases de novo CNVs across the malaria parasite genome.bioRxiv : the preprint server for biology · 2025Article
- Optimization and Characterization of the Antimalarial Activity ofJournal of medicinal chemistry · 2025Article
- Integrating Intermediate Traits in Phylogenetic Genotype-to-Phenotype Studies.Integrative and comparative biology · 2025Review
- Emerging Molecular Mechanisms in Malaria Pathogenesis and Novel Therapeutic Approaches: A Focus onBiomolecules · 2025Review
- Plasmodiumfalciparum protein kinase 6 and hemozoin formation are inhibited by a type II human kinase inhibitor exhibiting antimalarial activity.Cell chemical biology · 2025Article
- Predicting Plasmodium drug resistance through in vitro evolution.Trends in parasitology · 2025Article
- Stereospecific Resistance to N2-Acyl Tetrahydro-β-carboline Antimalarials Is Mediated by a PfMDR1 Mutation That Confers Collateral Drug Sensitivity.ACS infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors.
Madeline R Luth *Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0001-9059-1200
Karla P Godinez-Macias *Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0002-6323-0204
Daisy Chen *Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0001-6516-7029
John OkomboCenter for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-8680-2351
Vandana ThathyDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-7797-8638
Xiu ChengGlobal Health Drug Discovery Institute, Beijing, China.
Sindhu DaggupatiDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.ORCID 0009-0003-9947-7254
Heledd DaviesWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID 0000-0003-3475-0080
Satish K DhingraDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.
Jan M EconomyDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.ORCID 0009-0001-5148-0038
Rebecca C S EdgarBiological Chemistry and Drug Discovery, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, UK.ORCID 0000-0002-5974-8625
Maria G Gomez-LorenzoGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.ORCID 0000-0003-2065-1145
Eva S IstvanDepartment of Internal Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-8666-3248
Juan Carlos JadoDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.
Gregory M LaMonteDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.
Bruno MelilloChemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA, USA.ORCID 0000-0002-9708-5287
Sachel MokCenter for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-9605-0154
Sunil K NarwalDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-5476-9753
Tolla NdiayeDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.
Sabine OttilieDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0001-9797-2612
Sara Palomo DiazGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.ORCID 0000-0002-5487-4841
Heekuk ParkDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-5815-9717
Stella PeñaQuímica Farmacéutica, Departamento de Química Orgánica, Facultad de Química, Universidad de la República, Montevideo, Montevideo, Uruguay.
Frances RocamoraDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0002-2579-6733
Tomoyo Sakata-KatoGlobal Health Drug Discovery Institute, Beijing, China.ORCID 0000-0002-8089-5101
Jennifer L Small-SaundersCenter for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-6064-2249
Robert L SummersDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0003-0840-1784
Patrick K TumwebazeInfectious Diseases Research Collaboration, Kampala, Uganda.
Manu VanaerschotDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-9141-2347
Guoqin XiaDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-7666-9550
Tomas YeoDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-2923-6060
Ashley YouDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.
Francisco-Javier GamoGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.ORCID 0000-0002-1854-2882
Daniel E GoldbergDepartment of Internal Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0003-3529-8399
Marcus C S LeeWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.ORCID 0000-0002-4973-0915
Case W McNamaraCalibr, a division of The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-5754-3407
Daouda NdiayeCentre International de Recherche et de Formation en Génomique Appliquée et de Surveillance Sanitaire (CIGASS), Dakar, Senegal.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7953-7622
Stuart L SchreiberBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0003-1922-7558
Gloria SerraQuímica Farmacéutica, Departamento de Química Orgánica, Facultad de Química, Universidad de la República, Montevideo, Montevideo, Uruguay.ORCID 0000-0002-5474-6524
Jair Lage De Siqueira-NetoSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0001-9574-8174
Tina S Skinner-AdamsInstitute for Biomedicine and Glycomics and School of Environment and Science, Griffith University, Nathan, QLD, Australia.ORCID 0000-0001-7011-3850
Anne-Catrin UhlemannDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-9798-4768
Nobutaka KatoGlobal Health Drug Discovery Institute, Beijing, China.ORCID 0009-0008-0085-2285
Amanda K LukensDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-9560-7643
Dyann F WirthDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-8604-4455
David A FidockDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-6753-8938
Elizabeth A WinzelerDepartment of Pediatrics, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0002-4049-2113
Funding
Training Program in Basic Clinical GeneticsT32GM008666 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAMILTON, BRUCE A · 1998 to 2021
$8.6MDefining the resistome in P. falciparum: evolution and mechanismR01AI169892 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Daniel E. Goldberg, Elizabeth A Winzeler · 2023 to 2026
$4.4MDefining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug ResistanceR37AI050234 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2018 to 2026
$4.4MDefining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4MElucidating the molecular basis of piperaquine resistance in Plasmodium falciparumR01AI124678 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2016 to 2026
$4.3MPlasmodium Protein Kinase Focused Antimalarials DiscoveryR01AI172066 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI DEBOPAM CHAKRABARTI, NATHANAEL Schiander GRAY · 2022 to 2026
$3.9MNovel Antimalarials from FungiR01AI154777 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI CHAKRABARTI, DEBOPAM, CICHEWICZ, ROBERT HENRY · 2020 to 2024
$3.8MDiscovery of long-acting, chemoprotective antimalarial compoundsR01AI152533 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2020 to 2024
$3.5MDefining the targets of broad intervention antimalarial agentsR01AI103058 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WINZELER, ELIZABETH A · 2013 to 2016
$2.6MGraduate Training Program in BioinformaticsT32GM139790 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAFNA, VINEET, GAASTERLAND, THERESA · 2021 to 2025
$2.1MDefining the complex genetic basis of Plasmodium falciparum resistance to artemisinin and quinine and identifying resistance-refractory therapeuticsR01AI185559 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2024 to 2026
$1.9MThe genetic basis of emerging multidrug resistance in Plasmodium falciparum African malariaR01AI182318 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Sachel Mok · 2024 to 2026
$1.9MGates Foundation INV-008249NIAID NIH HHS R01 AI103058NIAID NIH HHS R01 AI109023NIAID NIH HHS R01 AI124678NIAID NIH HHS R01 AI152533NIAID NIH HHS R01 AI154777NIAID NIH HHS R01 AI169892NIAID NIH HHS R01 AI172066NIAID NIH HHS R01 AI182318NIAID NIH HHS R01 AI185559NIAID NIH HHS R37 AI050234NIGMS NIH HHS T32 GM008666NIGMS NIH HHS T32 GM139790NIH HHS S10 OD026929
Abstract
Surveillance of drug resistance and the discovery of novel targets-key objectives in the fight against malaria-rely on identifying resistance-conferring mutations in
Indexed as
AntimalarialsDirected Molecular EvolutionDrug ResistanceDrug Resistance, MultiplePlasmodium falciparumProtozoan ProteinsFrameshift MutationGenes, ProtozoanGenome, ProtozoanHumansMalaria, FalciparumMutation, MissenseProtein DomainsAntimalarialsProtozoan Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.